Literature DB >> 19203210

A sensitive cell-based assay to measure the doxycycline concentration in biological samples.

Wendy Kleibeuker1, Xue Zhou, Mireille Centlivre, Nicolas Legrand, Mark Page, Neil Almond, Ben Berkhout, Atze T Das.   

Abstract

Doxycycline (DOX) is widely used as a pharmacological agent and as an effector molecule in inducible gene expression systems. For most applications, it is important to determine whether the DOX concentration reaches the level required for optimal efficacy. We developed a sensitive bioassay for measuring the DOX concentration in biological samples. We used a modified HeLa cell line with the luciferase reporter gene under the control of the DOX-inducible Tet-On system for regulation of gene expression. These HeLaDOX cells constitutively express a novel variant of the rtTA transcriptional activator protein that is highly DOX-sensitive. Incubation of the cells with a DOX-containing biological sample triggers luciferase expression, which can be quantitated by standard methods. This bioassay is sensitive, with a DOX detection limit of 22 ng/ml in plasma. The assay was used to determine the DOX concentration in plasma derived from DOX-treated rhesus macaques and mice. Furthermore, we found that the DOX concentration in murine cerebrospinal fluid is 31-fold lower than the concurrent plasma DOX level. This bioassay for the quantification of DOX concentration in biological samples has several advantages over high-performance liquid chromatography-based and microbiological assays: (1) multiple samples can be assayed in a single experiment; (2) only small sample volumes are required; (3) the assay has a low detection limit; and (4) the assay can be performed in any cell culture laboratory.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19203210     DOI: 10.1089/hum.2008.182

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  9 in total

1.  A doxycycline-dependent human immunodeficiency virus type 1 replicates in vivo without inducing CD4+ T-cell depletion.

Authors:  Nicolas Legrand; Gisela J van der Velden; Raphaël Ho Tsong Fang; Marc Douaisi; Kees Weijer; Atze T Das; Bianca Blom; Christel H Uittenbogaart; Ben Berkhout; Mireille Centlivre
Journal:  J Gen Virol       Date:  2012-05-30       Impact factor: 3.891

2.  Design and Evaluation of Guide RNA Transcripts with a 3'-Terminal HDV Ribozyme to Enhance CRISPR-Based Gene Inactivation.

Authors:  Ben Berkhout; Zongliang Gao; Elena Herrera-Carrillo
Journal:  Methods Mol Biol       Date:  2021

3.  Role of Occult and Post-acute Phase Replication in Protective Immunity Induced with a Novel Live Attenuated SIV Vaccine.

Authors:  Neil Berry; Maria Manoussaka; Claire Ham; Deborah Ferguson; Hannah Tudor; Giada Mattiuzzo; Bep Klaver; Mark Page; Richard Stebbings; Atze T Das; Ben Berkhout; Neil Almond; Martin P Cranage
Journal:  PLoS Pathog       Date:  2016-12-21       Impact factor: 6.823

4.  A Single H1 Promoter Can Drive Both Guide RNA and Endonuclease Expression in the CRISPR-Cas9 System.

Authors:  Zongliang Gao; Elena Herrera-Carrillo; Ben Berkhout
Journal:  Mol Ther Nucleic Acids       Date:  2018-11-01

5.  Improvement of the CRISPR-Cpf1 system with ribozyme-processed crRNA.

Authors:  Zongliang Gao; Elena Herrera-Carrillo; Ben Berkhout
Journal:  RNA Biol       Date:  2018-11-29       Impact factor: 4.652

6.  Conditionally-live attenuated SIV upregulates global T effector memory cell frequency under replication permissive conditions.

Authors:  Maria S Manoussaka; Neil Berry; Deborah Ferguson; Richard Stebbings; Mark Robinson; Claire Ham; Mark Page; Bo Li; Atze T Das; Ben Berkhout; Neil Almond; Martin P Cranage
Journal:  Retrovirology       Date:  2013-06-05       Impact factor: 4.602

7.  Inducible and reversible lentiviral and Recombination Mediated Cassette Exchange (RMCE) systems for controlling gene expression.

Authors:  David C Bersten; Adrienne E Sullivan; Dian Li; Veronica Bhakti; Stephen J Bent; Murray L Whitelaw
Journal:  PLoS One       Date:  2015-03-13       Impact factor: 3.240

8.  A regulatable AAV vector mediating GDNF biological effects at clinically-approved sub-antimicrobial doxycycline doses.

Authors:  Abdelwahed Chtarto; Marie Humbert-Claude; Olivier Bockstael; Atze T Das; Sébastien Boutry; Ludivine S Breger; Bep Klaver; Catherine Melas; Pedro Barroso-Chinea; Tomas Gonzalez-Hernandez; Robert N Muller; Olivier DeWitte; Marc Levivier; Cecilia Lundberg; Ben Berkhout; Liliane Tenenbaum
Journal:  Mol Ther Methods Clin Dev       Date:  2016-03-30       Impact factor: 6.698

Review 9.  Tet-On Systems For Doxycycline-inducible Gene Expression.

Authors:  Atze T Das; Liliane Tenenbaum; Ben Berkhout
Journal:  Curr Gene Ther       Date:  2016       Impact factor: 4.391

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.